About 40% of AML patients exhibit increased activity of the NF-kB signaling pathway, and it is constitutively active in CD34+/CD38- blasts from M1, M2, M4, and M5 AML patients [94,95]. This evidence concerns the gene CD38 and acute myeloid leukemia.